Apollo Endosurgery, Inc. Sustainability Profile
Apollo Endosurgery, Inc., a leading innovator in the medical device industry, is headquartered in the United States. Founded in 2006, the company has established itself as a pioneer in minimally invasive surgical solutions, particularly in the fields of bariatric and gastrointestinal procedures. With a focus on advanced endoscopic technologies, Apollo Endosurgery offers unique products such as the OverStitch™ Endoscopic Suturing System and the ORBERA® Managed Weight Loss System. These solutions are designed to enhance patient outcomes while minimising recovery times. Recognised for its commitment to innovation, Apollo Endosurgery has achieved significant milestones, positioning itself as a trusted partner in the healthcare community. The company continues to expand its operational reach, serving major markets across North America and beyond, while striving to improve the quality of care for patients worldwide.
DitchCarbon Score
How does Apollo Endosurgery, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apollo Endosurgery, Inc.'s score of 97 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apollo Endosurgery, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Boston Scientific Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family relationship, Apollo Endosurgery inherits climate initiatives and targets from Boston Scientific Corporation. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the level of Boston Scientific. However, specific reduction targets or achievements for Apollo Endosurgery have not been disclosed. While no direct emissions data or reduction targets are available for Apollo Endosurgery, the company's alignment with Boston Scientific's sustainability efforts suggests a commitment to addressing climate change and reducing carbon footprints in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Apollo Endosurgery, Inc.'s Industry?
How Carbon Intensive is Apollo Endosurgery, Inc.'s Location?
Apollo Endosurgery, Inc.'s Scope 3 Categories Breakdown
Apollo Endosurgery, Inc.'s Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Apollo Endosurgery, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Apollo Endosurgery, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
